Medigene Immunotherapies GmbH, part of MediGene AG, is a company headquartered in Planegg, Germany. The firm develops immunotherapy to treat cancer. It was founded in 2013 by Thomas Blankenstein and Dolores J. Schendel. Axel-Sven Malkomes is currently the CEO of the company. Medigene Immunotherapies GmbH was acquired by MediGene AG on January 27, 2014 for $13.05 million.\nThe company says this about itself: Based on more than 15 years of extensive research in the field of immunotherapy, Medigene Immunotherapies GmbH (formerly Trianta Immunotherapies GmbH) was founded late 2013 as a spin-off of the Helmholtz Zentrum München and was acquired by Medigene as a 100%subsidiary in January 2014. Medigene Immunotherapies pursues three complementary immunotherapeutic strategies to target various tumour types and stages: next generation antigen-tailored dendritic cell (DC)vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Triumvira Immunologics USA, Inc. is an American company located in Austin, TX, with subsidiaries in Canada, that develops and manufactures novel T cell therapies for cancer. Paul Lammers has been the CEO of the firm since 2018.\nThe company says this about itself: Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology. Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date. Triumvira��s pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years. Supporting the pipeline has been an industrialized, drug-like, approach to manufacturing, including the first-mover adoption of the Lonza Cocoon�� Platform that has yielded high quality product and a very high manufacturing success rate at a lower cost compared to other autologous approaches. Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.

Part of Aptevo Therapeutics, Inc., Aptevo Research & Development LLC is a company headquartered in Olympia, WA. The firm engages in research and development of pharmaceutical and biotechnology.

Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA.

22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.

Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Xiangxue Life Science Technology (Guangdong) Co., Ltd., established on 2020-12-23, Business scope includes general items:R&D and application of cell technology;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Drug import and export;pharmaceutical production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK

ARCH Development Corp., part of The University of Chicago, is an American company that provides job training and housing development services. Duane Gautier is currently the CEO of the firm.

China Immunotech is a small molecule innovative drug R&D company developing immune cell therapy technologies and products. Including CAR-T and TCR-T cell therapy with independent intellectual property rights. It was founded in March 2018 by famous immunologists.

Careji (Beijing) Life Technology Co., Ltd., established on 2019-01-30, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of industrial control computers and systems;Retailing of computer software, hardware and auxiliary equipment;software development;Wholesale of computer software, hardware and auxiliary equipment;Educational Consulting Services(Education and training activities that do not include licensing approval);Organize cultural and artistic exchange activities;Conference and Exhibition Services;literary creation;Natural science research and experimental development;R&D and application of cell technology;Health Consulting Services(Does not include medical services);translation service;Data processing and storage support services;Engineering and Technology Research and Experimental Development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Huaxia Yuan Cell Engineering Group Co., Ltd., established on 2015-10-26, Business scope includes general items:Engaged in tissue and cell storage,cell preparation,Technical services for human genetic diagnosis and treatment,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals),Human stem cell technology development and application,Medical Research and Experimental Development,Engineering and Technology Research and Experimental Development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

Immunocore Ltd., part of Immunocore Holdings Plc, is a company headquartered in Oxon, UK. The firm develops and commercializes transformative medicines for cancer, infection and autoimmune disease. It was founded in 2007. Bahija Jallal is the current CEO of the firm.\nThe company says this about itself: Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.

Trustees of Dartmouth College, part of Dartmouth College, is a company headquartered in Hanover, NH. The firm operates higher education institutes. It was founded in 1769.

Genecraft GmbH is a German private company that provides nucleotides, kits and mixtures for molecular biology products.

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.